Cisplatin-based chemoradiotherapy vs. cetuximab-based bioradiotherapy for p16-positive oropharyngeal cancer: an updated meta-analysis including trials RTOG 1016 and De-ESCALaTE

Purpose Human papilloma virus (HPV)-associated oropharyngeal cancer (OPC) is a special entity among head and neck squamous cell carcinomas (HNSCCs). Given its favorable prognosis, one of the de-escalating strategies in the treatment of OPC includes the introduction of cetuximab (C225) instead of cis...

Full description

Saved in:
Bibliographic Details
Published in:European archives of oto-rhino-laryngology 2019-05, Vol.276 (5), p.1275-1281
Main Authors: Suton, Petar, Skelin, Marko, Rakusic, Zoran, Dokuzovic, Stjepan, Luksic, Ivica
Format: Article
Language:English
Subjects:
Adult
Aged
Antineoplastic Agents - administration & dosage
Cetuximab - administration & dosage
Chemoradiotherapy
Cisplatin - administration & dosage
Female
Head and Neck Surgery
Humans
Male
Medicine
Medicine & Public Health
Middle Aged
Neoplasm Recurrence, Local - epidemiology
Neurosurgery
Odds Ratio
Oropharyngeal Neoplasms - mortality
Oropharyngeal Neoplasms - therapy
Oropharyngeal Neoplasms - virology
Otorhinolaryngology
Papillomaviridae
Review Article
Squamous Cell Carcinoma of Head and Neck - mortality
Squamous Cell Carcinoma of Head and Neck - therapy
Squamous Cell Carcinoma of Head and Neck - virology
Survival Analysis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose Human papilloma virus (HPV)-associated oropharyngeal cancer (OPC) is a special entity among head and neck squamous cell carcinomas (HNSCCs). Given its favorable prognosis, one of the de-escalating strategies in the treatment of OPC includes the introduction of cetuximab (C225) instead of cisplatin (CDDP) in conjunction with radiotherapy. An updated meta-analysis of published studies has been performed, which directly compared the efficacy of CDDP vs. C225 given concurrently with radiotherapy as definitive treatment of p16-positive OPC. Methods A systematic literature search was performed for studies published between 2006 and 2018. A total of 1490 citations were obtained and 8 studies met inclusion criteria, with a total of 1665 patients. Results The data from seven studies were available for the analysis of 2-year overall survival (OS). Calculated pooled OR for CDDP-based chemoradiotherapy vs. C225-based bioradiotherapy, was 0.45 ( P  
ISSN:0937-4477
1434-4726
DOI:10.1007/s00405-019-05387-8